Evidence map›Paper›PMID 35340265›Full record

ArticleFrontiers in oncology2022

Epstein-Barr Virus in Burkitt Lymphoma in Africa Reveals a Limited Set of Whole Genome and

Hsiao-Mei Liao, Hebing Liu, Pei-Ju Chin, Bingjie Li, Guo-Chiuan Hung, Shien Tsai, Isaac Otim, Ismail D Legason, Martin D Ogwang, Steven J Reynolds and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 4 countries.

Hsiao-Mei LiaoOffice of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
Hebing LiuOffice of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
Pei-Ju ChinOffice of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
Bingjie LiOffice of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
Guo-Chiuan HungOffice of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
Shien TsaiOffice of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
Isaac OtimEMBLEM Study, St. Mary's Hospital, Lacor, Gulu & African Field Epidemiology Network, Kampala, Uganda.
Ismail D LegasonEMBLEM Study, African Field Epidemiology Network, Kampala, Uganda.
Martin D OgwangEMBLEM Study, St. Mary's Hospital, Lacor, Gulu & African Field Epidemiology Network, Kampala, Uganda.
Steven J ReynoldsDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Patrick KerchanEMBLEM Study, African Field Epidemiology Network, Kampala, Uganda.
Constance N TengeEMBLEM Study, African Field Epidemiology Network, Kampala, Uganda.
Pamela A WereEMBLEM Study, African Field Epidemiology Network, Kampala, Uganda.
Robert T KuremuEMBLEM Study, African Field Epidemiology Network, Kampala, Uganda.
Walter N WekesaEMBLEM Study, African Field Epidemiology Network, Kampala, Uganda.
Nestory MasaluEMBLEM Study, African Field Epidemiology Network, Kampala, Uganda.
Esther KawiraEMBLEM Study, African Field Epidemiology Network, Kampala, Uganda.
Leona W AyersDepartment of Pathology, The Ohio State University, Columbus, OH, United States.
Ruth M PfeifferDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Kishor BhatiaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
James J GoedertDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Shyh-Ching LoOffice of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
Sam M MbulaiteyeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Center for Biologics Evaluation and Research · USAfrican Field Epidemiology Network · UGMoi University · KENational Cancer Institute · USAMPATH · KEBugando Medical Centre · TZKuluva Hospital · UGNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USThe Ohio State University · US

Funding

Epidemiology and Natural History of Cancer-Associated VirusesZIACP010176 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MBULAITEYE, SAM M · 2009 to 2025
$33.7M
International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
NCI NIH HHS HHSN261201100007INCI NIH HHS HHSN261201100063CNHLBI NIH HHS HHSN261201100007C
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) is associated with endemic Burkitt lymphoma (eBL), but the contribution of EBV variants is ill-defined. Studies of EBV whole genome sequences (WGS) have identified phylogroups that appear to be distinct for Asian versus non-Asian EBV, but samples from BL or Africa, where EBV was first discovered, are under-represented. We conducted a phylogenetic analysis of EBV WGS and Lay Summary: Epstein-Barr virus (EBV) infection, a ubiquitous infection, contributes to the etiology of both Burkitt Lymphoma (BL) and nasopharyngeal carcinoma, yet their global distributions vary geographically with no overlap. Genomic variation in EBV is suspected to play a role in the geographical patterns of these EBV-associated cancers, but relatively few EBV samples from BL have been comprehensively studied. We sought to compare phylogenetic patterns of EBV genomes obtained from BL samples in Africa and from tumor and non-tumor samples from elsewhere. We concluded that EBV obtained from BL in Africa is genetically separate from EBV in Asia. Through comprehensive analysis of nucleotide variations in EBV's

Indexed as

Burkitt lymphomachildhood cancerEast AfricaEBV variantsepidemiologyEpstein-Barr virusLMP-1 patterns

Identifiers

PMID35340265
PMCPMC8948429
OpenAlexW4221110474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.